Skip to main content
Shanghai Hile Bio-Technology Co.,Ltd logo

Shanghai Hile Bio-Technology Co.,Ltd — Investor Relations & Filings

Ticker · 603718 ISIN · CNE1000022T4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,480 across all filing types
Latest filing 2025-08-27 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603718

About Shanghai Hile Bio-Technology Co.,Ltd

http://www.hile-bio.com/

Shanghai Hile Bio-Technology Co., Ltd. specializes in the research, development, production, and distribution of veterinary biological products. The company focuses on providing comprehensive health solutions for the livestock and poultry sectors. Its core product portfolio includes a wide range of vaccines targeting major animal diseases, such as swine fever, porcine reproductive and respiratory syndrome (PRRS), foot-and-mouth disease, and various avian influenza strains. Utilizing advanced biotechnology and large-scale manufacturing processes, the company operates high-standard production facilities compliant with Good Manufacturing Practice (GMP) requirements. Hile Bio-Technology emphasizes innovation through its dedicated research and development centers, aiming to enhance animal disease prevention and control. The company serves large-scale farming enterprises and veterinary service providers, maintaining a significant presence in the animal health sector through its commitment to product quality and technical support.

Recent filings

Filing Released Lang Actions
海利生物募集资金管理制度
Governance Information Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the rules and procedures for the management, storage, and use of funds raised by the company. It references regulatory frameworks related to securities issuance and fundraising, outlines internal controls, approval processes, and reporting requirements for the use of raised capital. The document is a detailed policy or management system document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results but rather governance and procedural rules regarding capital raised. This fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices related to capital management.
2025-08-27 Chinese
海利生物董事会战略委员会议事规则
Governance Information Classification · 95% confidence The document is titled "董事会战略委员会议事规则" which translates to "Board Strategic Committee Meeting Rules." It details the composition, responsibilities, meeting procedures, and operational rules of the company's strategic committee under the board of directors. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, no earnings information, and no presentation or transcript content. The document is a governance-related internal rules document describing board committee structure and procedures. Therefore, it fits the category of Governance Information (CGR). The document length is 3298 characters, which is sufficient for a detailed governance document but not a short announcement. Hence, the classification is CGR with high confidence.
2025-08-27 Chinese
海利生物董事会审计委员会议事规则
Governance Information Classification · 95% confidence The document is titled "董事会审计委员会议事规则" which translates to "Board Audit Committee Rules". It details the composition, responsibilities, meeting procedures, and operational rules of the Audit Committee of the Board of Directors of Shanghai Haili Biotechnology Co., Ltd. The content focuses on governance, audit oversight, and internal control processes rather than presenting financial data, audit results, or financial statements. There is no indication that this is an audit report, annual report, or any financial statement. Instead, it is a governance document outlining internal rules and procedures related to the audit committee. Therefore, the document fits best under Governance Information (CGR). The document length (5398 characters) and detailed procedural content support this classification rather than a brief announcement or a report publication announcement.
2025-08-27 Chinese
海利生物第五届监事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the eighth meeting of the fifth Supervisory Board of Shanghai Haili Biotechnology Co., Ltd. It includes details about the meeting's legality, attendance, and the approval of the 2025 semi-annual report and other governance matters. The document does not contain the semi-annual report itself but rather the Supervisory Board's approval and statements regarding the report's compliance and accuracy. It also references other announcements and documents disclosed elsewhere. The document length is short (1006 characters), and it serves as an official meeting resolution announcement rather than the full interim report or financial statements. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2025-08-27 Chinese
海利生物会计师事务所选聘制度
Governance Information Classification · 95% confidence The document is titled '上海海利生物技术股份有限公司 会计师事务所选聘制度' which translates to 'Shanghai Haili Biotechnology Co., Ltd. Auditor Selection System'. The content details the procedures, requirements, and regulations for selecting and appointing an accounting firm (auditor) for the company. It includes sections on general principles, quality requirements, selection procedures, replacement conditions, supervision, and penalties related to the appointment of auditors. There is no financial data, audit results, or report disclosures present. Instead, it is a governance or procedural document related to auditor appointment and oversight. This fits best under Governance Information (CGR), which covers internal rules and governance practices. The document length is over 6000 characters, indicating it is a full policy document rather than a brief announcement or regulatory filing. Therefore, the classification is CGR with high confidence.
2025-08-27 Chinese
海利生物对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '对外投资管理制度' which translates to 'External Investment Management System' and outlines the company's policies and procedures for managing external investments. It includes sections on general principles, decision-making authority, daily management, transfer and recovery of investments, reporting and disclosure obligations, and other administrative details. There are no financial statements, earnings data, or regulatory filings such as audit reports or annual reports. The document is a governance-related internal policy document rather than a report or announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is best classified under Governance Information (CGR) as it details the company's internal rules and governance practices related to external investments.
2025-08-27 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.